IIT Roorkee Current Affairs - 2019
Category Wise PDF Compilations available at This Link
The London-based Times Higher Education (THE), a global organisation that produces data, analysis and expertise on higher education has released the Emerging Economies University Rankings 2019. The 2019 ranking comprises of 450 universities from 43 countries, across four continents.
The rankings use 13 performance indicators to provide comprehensive and balanced comparisons to reflect the characteristics of the emerging economy universities.
These 13 performance indicators are grouped under 5 categories: Teaching (the learning environment); Research (volume, income and reputation); citations (research influence); International outlook (staff, students and research); and industry income (knowledge transfer).
Findings in the Rankings
The standings of Indian universities in the rankings are as outlined below:
- The Indian Institute of Science has topped the rankings among Indian institutes with 14th rank; the second spot among Indian Institutes was occupied by the Indian Institute of Technology Bombay with 27th rank.
- IIT Roorkee has moved up by 21 places to 35th rank due to improvements in its research (volume, income and reputation) and industry income (knowledge transfer).
- IIT Indore (61st) and the JSS Academy of Higher Education and Research are at joint 64th position.
- Savitribai Phule Pune University has moved up by 87 positions to joint 93rd, alongside the National Autonomous University of Mexico. The increase in the rankings of Savitribai Phule Pune University is attributed to its research score and a significant rise to its citations score.
- Banaras Hindu University, Amrita University, Indian Institute of Science Education and Research, Pune and IIT Hyderabad also features among the top 150 in the rankings.
The Universities of Mainland China are most represented in the rankings with 72 institutions in total.
Tags: Amrita University • Banaras Hindu University • Emerging Economies University Rankings 2019 • IIT Hyderabad • IIT Indore • IIT Roorkee • Indian Institute of Science • Indian Institute of Science Education and Research • Indian Institute of Technology Bombay • JSS Academy of Higher Education and Research • Savitribai Phule Pune University • Times Higher Education
Researchers from Indian Institute of Technology (IIT) Roorkee have identified two small potent molecules Pep-I and Pep-II, for their inhibitory activity to treat Chikungunya disease. The antiviral activity of these molecules was so high that their small amount was able to achieve almost 99% reduction in virus. Currently, there are no drugs to treat chikungunya or any vaccine to prevent it.
The antiviral activity was tested by adding molecules directly into virus culture. Using structure-based studies of chikungunya virus-specific nsP2 protease, researchers had identified two small molecules Pep-I and Pep-II for their inhibitory activity against vector borne disease.
Protease inhibitors have already been used successfully against HIV and hepatitis C virus. Pep-I, one of two molecules has superior antiviral activity against chikungunya virus. It was found to effectively bind to protein of virus (nsP2 protease) and prevent virus from replicating. It is hypothesised that any molecule that inhibits nsP2 protease is having antiviral activity.
During studies it was confirmed that both molecules have significant ability to kill virus. Pep-I molecule was very efficient in killing the virus, 99% reduction in virus at 5 microMolar and Pep-II molecule showed reduced antiviral activity of only 50% even at a higher concentration of about 200 microMolar. The two molecules also reduced viral RNA thus confirming the antiviral activity.
Chikungunya is a mosquito-borne virus that causes a disease. It is transmitted by Aedes aegypti and Aedes albopictus mosquitoes. Its symptoms are characterised by abrupt fever and severe joint pain, often in hands and feet, and may include headache, muscle pain, joint swelling or rash.
There is no specific antiviral drug treatment for chikungunya. There is no commercial vaccine to treat chikungunya. Chikungunya treatment is directed primarily at relieving the symptoms, including the joint pain using anti-pyretics, optimal analgesics and fluids.